Genetix acquisition expands range and scope - Applied Imaging products enhance existing cell biology portfolio

2 March 2007: Innovative UK-based company, Genetix Ltd (New Milton, UK), has completed the acquisition of Applied Imaging Corp (San Jose, USA). Through the integration of Genetix breakthrough cell biology platforms (ClonePix FL and CloneSelect Imager) and Applied Imaging’s Ariol and CytoVision product lines, the company can now deliver systems that track the progress of drug discovery from the research laboratory through to the clinic.

ClonePix FL and CloneSelect Imager, along with their dedicated reagents and consumables, have revolutionised the generation, selection and management of mammalian cell lines for biopharmaceutical and drug discovery. Eliminating laborious manual procedures and screening very large numbers of cells rapidly, Genetix systems shorten timescales from weeks to days. Cell culture is simplified, turning large scale, high throughput screening from a facility-based activity into a benchtop process.

The Ariol pathology instrumentation and the CytoVision software, enable the nature of tumours to be studied at protein biomarker level. This is invaluable in the drug discovery process - for target discovery and as a monitor of therapeutic response and predictor of treatment effectiveness.

To find out more, contact your local Genetix organisation, or visit: www.genetix.com 

A high resolution image is available from Richard Kent at
Kapler Communications (email : richard@kapleronline.com )
Please quote reference GEN/JOB/041



Notes to Editors
Genetix delivers pioneering, technological breakthroughs that give customers the competitive edge to find the cells and push the boundaries in biopharmaceutical and clinical research. It supplies major international Pharmaceutical and Biotechnology companies involved in the drug discovery process including GSK, Merck, Genentech, Wyeth, Novartis, as well as many leading academic institutions world-wide.

Genetix achievements have helped revolutionize cell biology, proteomics and genomics. The company made a significant contribution to the Human Genome Project by supplying high-throughput equipment to seven of the leading eight laboratories of the consortium. Today, through its R&D expertise and scientific resource, Genetix is committed to the continual development of innovative solutions to accelerate the rate of Translational Biology.

Genetix is quoted on the London Stock Exchange (symbol GTX) and is based in New Milton, Hampshire, UK.

Applied Imaging (AI) leads the world in the genetic testing and cancer pathology markets. More clinicians and researchers use AI genetic testing systems worldwide than any other imaging analysis platform.

The company’s imaging analysis products provide physicians and other health-care workers with the highly accurate, quantitative data to make the right decisions in diagnosis and therapy selection.

With corporate headquarters in Silicon Valley, California and international operations located in Newcastle, UK, Applied Imaging provides support for its customers and partners throughout the world. A comprehensive, international product distributor network ensures customers an attentive local presence, backed up globally by highly trained experts.

Enquiries: Media enquiries
Genetix Limited                                                  Kapler Communications Ltd
Hilary Latham, Marketing Manager                Richard Kent, Director
Tel: +44 (0) 1425 624 600                               Tel: +44 (0) 1480 471 117
hilary.latham@genetix.com                             richard@kapleronline.com